| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC12145 | DLinDMA Featured | DLinDMA is a key lipid component of stable nucleic acid lipid particles as a benchmark. |
|
| DC12381 | DLin-KC2-DMA Featured | DLin-KC2-DMA is 100-fold and 1000-fold more potent, respectively, in silencing of a hepatic gene (Factor VII) in comparison to the previous generation lipid DLin-DMA. |
|
| DC11486 | D-Luciferin (potassium salt) Featured | D-Luciferin is a chemiluminescent substrate of firefly luciferase. |
|
| DC9287 | D-Luciferin Featured | D-Luciferin is a popular bioluminescent substrate of luciferase in the presence of ATP, used in luciferase-based bioluminescence imaging and cell-based high-throughput screening applications. Cas: 2591-17-5 |
|
| DC11426 | DM1-PEG4-DBCO Featured | DM1-(PEG)4-DBCO (DBCO-PEG4-DM1) is made by DM1 conjugated to DBCO-(PEG)4 linker.DM1 (mertansine), a thiol-containing maytansinoid, is a potent microtubule-disrupting agent. |
|
| DC8539 | DM1-SMCC Featured | DM1-SMCC is DM1 with a reactive linker SMCC, which can react with antibody to make antibody drug conjugate. |
|
| DC11396 | DM1-SMe Featured | DM1-SMe is a potent maytansinoid microtubular inhibitor and an unconjugated DM1 as a mixed disulfide with thiomethane to cap its sulfhydryl group. |
|
| DC9401 | DMAT(CK2 Inhibitor) Featured | DMAT is a potent and specific CK2 inhibitor with an IC50 of 0.13 uM. |
|
| DC7643 | DMH1 Featured | DMH1 is a selective BMP receptor inhibitor with IC50 of 107.9 nM for ALK2, exhibiting no inhibition on AMPK, ALK5, KDR (VEGFR-2) or PDGFR. |
|
| DC7403 | Dimethyloxaloylglycine(DMOG) Featured | DMOG is a cell permeable prolyl-4-hydroxylase inhibitor, which upregulates HIF (hypoxia-inducible factor). |
|
| DC9434 | DMP 777 | DMP 777(L-694458) is a potent, selective, and orally active human leukocyte elastase (HLE) inhibitor. |
|
| DC20600 | DM-PIT-1 Featured | DM-PIT-1 is a specific PIP3 antagonist that disrupts PIP3/Akt PH domain, PIP3/PDK1 PH domain, and PIP3/GRP1 PH domain with IC50 of 27.1 uM, 80.5 uM, and 35.5 uM, respectively. |
|
| DC12079 | DMU2105 | DMU2105 is a potent and specific CYP1B1 inhibitor, with IC50s of 10, 742 nM for CYP1B1 and CYP1A1, respectively. |
|
| DC11473 | DMU-2105(CYP1B1 inhibitor 7k) Featured | DMU-2105(CYP1B1 inhibitor 7k) is a potent and specific CYP1B1 inhibitor. |
|
| DC22291 | DMU-212（resveratrol analog） Featured | DMU-212, a methoxylated resveratrol analog, has significant anticancer activity, and selectively targets tumor cells. |
|
| DC22307 | DMX-5804 Featured | DMX-5804 is a potent, orally active and selective MAP4K4 inhibitor, with an IC50 of 3 nM, a pIC50 of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC50, 8.18), and TNIK/MAP4K7 (pIC50, 7.96). |
|
| DC7404 | DMXAA Featured | DMXAA (Vadimezan) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM, respectively. Phase 3. |
|
| DC20959 | DNDI-8219 | DNDI-8219 is a novel potent, orally active antileishmanial agent with IC50 of 0.19 uM against Leishmania donovani (L. don). |
|
| DC23671 | DNMDP | DNMDP is a potent and selective cancer cell cytotoxic agent that binds to PDE3A, promotes an interaction between PDE3A and Schlafen 12 (SLFN12). |
|
| DC11337 | MMP Substrate II Control | Dnp-GPLG is a peptide for use as a negative control for activity of matrix metalloproteinases (MMPs) that cleave peptides containing the sequence Dnp-GPLG. |
|
| DC11342 | MMP-1 Fluorogenic Substrate III | Dnp-P-Cha-Abu-Cys(Me)-HA-K(Nma)-NH2 is a fluorogenic substrate for matrix metalloproteinase-1 (MMP-1) and MMP-9. |
|
| DC11348 | MMP-1/MMP-9 Fluorogenic Substrate Featured | Dnp-P-Cha-G-Cys(Me)-HA-K(Nma)-NH2 is a fluorogenic substrate for matrix metalloproteinase-1 (MMP-1) and MMP-9 |
|
| DC11351 | MMP-1 Fluorogenic Substrate I Featured | Dnp-PLALWAR is a fluorogenic substrate for matrix metalloproteinase-1 (MMP-1) and MMP-8. |
|
| DC11339 | MMP-8/MMP-26 Fluorogenic Substrate Featured | Dnp-PLAYWAR is a fluorogenic substrate for matrix metalloproteinase-8 (MMP-8) and MMP-26.The activity of MMP-8 and MMP-26 can be quantified by measuring tryptophan fluorescence that is unquenched upon peptide hydrolysis that removes the N-terminal dinitro |
|
| DC11347 | MMP-1 Substrate II Featured | Dnp-PLG-Cys(Me)-HA-DArg-NH2 is a peptide substrate for matrix metalloproteinase-1 (MMP-1).It has an improved kcat/Km ratio compared with the MMP-1 flurogenic substrate Dnp-PLGLWA-DArg-NH2. |
.png)
|
| DC11344 | MMP-2/MMP-9 Fluorogenic Substrate I | Dnp-PLGMWSR is a fluorogenic substrate for matrix metalloproteinase-2 (MMP-2) and MMP-9.The activity of MMP-2 and MMP-9 can be quantified by measuring tryptophan fluorescence that is unquenched upon peptide hydrolysis that removes the N-terminal dinitroph |
|
| DC11345 | MMP-7 Fluorogenic Substrate | Dnp-RPLALWRS is a fluorogenic substrate for matrix metalloproteinase-7 (MMP-7).The activity of MMP-7 can be quantified by measuring tryptophan fluorescence that is unquenched upon peptide hydrolysis that removes the N-terminal dinitrophenol (Dnp) group. |
|
| DC10673 | DNQX disodium salt Featured | DNQX is a elective non-NMDA antagonist |
|
| DC10672 | DNQX Featured | DNQX is a elective non-NMDA antagonist |
|
| DC21509 | DNS-pE | DNS-pE (PHGDH Fluorescent Probe DNS-pE) is the first small molecule that can selectively label endogenous 3-phosphoglycerate dehydrogenase (PHGDH) from various mammalian cells. |
|
